Activators of the BC051019 protein, known as BC051019 activators, are a chemical class designed to upregulate the activity of this specific protein. The journey of identifying these molecules typically begins with high-throughput screening (HTS), which is an automated process that can rapidly test a large number of compounds for their ability to affect the activity of BC051019. During this phase, a diverse chemical library is screened against the target protein, using assays that are quantitative and produce measurable signals like fluorescence or luminescence when BC051019 activity is altered. Compounds that show an increase in the activity of the BC051019 protein are considered hits and are selected for further validation. Secondary assays, which are more specific and stringent than the primary HTS, are then conducted to ensure that these hits are indeed true activators of BC051019. These secondary tests help to filter out any non-specific activators or compounds that produce a signal through an indirect mechanism unrelated to BC051019 activation.
Following the identification and validation of potential BC051019 activators, a detailed characterization of their interaction with the BC051019 protein is undertaken. Techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy can be employed to elucidate the structural details of the activator-BC051019 complex. These structural insights are crucial for understanding how these activators enhance the protein's activity by revealing the binding sites and conformational changes induced upon interaction. Additionally, biophysical methods like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to obtain quantitative information about the binding kinetics and affinity of the activators to BC051019. This data allows for the determination of how readily the activators bind to the protein and the strength of the interaction. Furthermore, structure-activity relationship (SAR) studies play a critical role in the optimization process.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels, potentially activating calcium-dependent proteins, which could include "BC051019" if it is calcium-sensitive. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator which could enhance the activity of "BC051019" if it is modulated by PKC-mediated phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that could potentially enhance the activity of "BC051019" by inhibiting competing kinase pathways, thus indirectly influencing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could enhance the activity of "BC051019" by altering signaling pathways downstream of PI3K if "BC051019" is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that could shift the balance of signaling towards pathways involving "BC051019" if it is part of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially enhancing pathways that "BC051019" is part of if it is negatively regulated by p38 MAPK signaling. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, enhancing calcium-dependent pathways, and could increase the activity of "BC051019" if it is calcium-regulated. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5 like Sildenafil and could similarly enhance "BC051019" activity if it is involved in cGMP-mediated signaling. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits Rac1-GEF interaction, which could enhance "BC051019" activity if it is involved in cell signaling pathways regulated by Rac1. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
This compound inhibits GSK3β, which could lead to the activation of "BC051019" if it is regulated by GSK3β-dependent phosphorylation. | ||||||